Last reviewed · How we verify
long-acting Octreotide.
Long-acting octreotide is a somatostatin analog that binds to somatostatin receptors to inhibit the secretion of various hormones and growth factors.
Long-acting octreotide is a somatostatin analog that binds to somatostatin receptors to inhibit the secretion of various hormones and growth factors. Used for Acromegaly, Neuroendocrine tumors (carcinoid syndrome, VIPomas), Gastroenteropancreatic neuroendocrine tumors.
At a glance
| Generic name | long-acting Octreotide. |
|---|---|
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Drug class | Somatostatin analog |
| Target | Somatostatin receptors (SSTR2, SSTR5) |
| Modality | Small molecule |
| Therapeutic area | Oncology; Endocrinology |
| Phase | Phase 3 |
Mechanism of action
Octreotide mimics the natural hormone somatostatin by binding to somatostatin receptors (particularly SSTR2 and SSTR5) on neuroendocrine cells and tumor cells. This binding suppresses the release of growth hormone, insulin, glucagon, and other hormones, as well as inhibiting angiogenesis and tumor cell proliferation. The long-acting formulation provides sustained therapeutic levels over weeks to months.
Approved indications
- Acromegaly
- Neuroendocrine tumors (carcinoid syndrome, VIPomas)
- Gastroenteropancreatic neuroendocrine tumors
Common side effects
- Diarrhea
- Abdominal pain
- Nausea
- Cholelithiasis
- Hyperglycemia
- Injection site reactions
Key clinical trials
- Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET (PHASE3)
- Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET (PHASE3)
- A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (PHASE1)
- Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors (PHASE2, PHASE3)
- Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors (PHASE3)
- Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours (PHASE2)
- A Phase III Clinical Study to Compare the Safety and Efficacy of 177Lu-DOTATATE Injection and Long-acting Oxytrexine in Adult Patients With NETs (PHASE3)
- A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |